Dahuang Zhechong Pill Improves Pulmonary Fibrosis through miR-29b-2-5p/HK2 Mediated Glycolysis Pathway

Xiao-Yan He1, Jing-Tao Liang2, Jing-Yi Xiao1

  • 1College of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.

Abstract

Insights

Dahuang Zhechong Pill (DZP) can treat pulmonary fibrosis by reducing glycolysis and inhibiting fibroblast activity. This traditional Chinese medicine utilizes the miR-29b-2-5p/HK2 pathway to slow fibrosis progression.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Pulmonary fibrosis is a debilitating lung disease characterized by excessive extracellular matrix deposition.
  • Glycolysis plays a critical role in the proliferation and differentiation of lung fibroblasts, key drivers of fibrosis.
  • Dahuang Zhechong Pill (DZP) is a traditional Chinese medicine with potential anti-fibrotic properties.

Purpose of the Study:

  • To investigate the preventive and therapeutic effects of DZP on pulmonary fibrosis.
  • To elucidate the underlying molecular mechanisms, focusing on the miR-29b-2-5p/HK2 pathway and glycolysis.

Main Methods:

  • Silencing and overexpression of hexokinase 2 (HK2) in MRC-5 lung fibroblasts.
  • Assessing cell viability, migration, invasion, proliferation, and apoptosis.
  • Measuring glucose, ATP, and lactate levels.
  • Investigating the miR-29b-2-5p and HK2 interaction using luciferase reporter assays.
  • Inducing pulmonary fibrosis in vitro and treating with DZP-medicated serum (DMS).

Main Results:

  • HK2 manipulation significantly altered fibroblast proliferation, migration, invasion, and apoptosis.
  • DZP treatment reduced glycolysis, HK2 expression, and extracellular matrix deposition (fibronectin, α-smooth muscle actin, collagen I) in fibrotic lung cells.
  • The miR-29b-2-5p/HK2 pathway was confirmed to be involved in DZP's anti-fibrotic effects.

Conclusions:

  • Glycolysis is a critical factor in pulmonary fibrosis development.
  • DZP exerts anti-fibrotic effects by modulating glycolysis via the miR-29b-2-5p/HK2 pathway.
  • DZP shows therapeutic potential for pulmonary fibrosis by inhibiting fibroblast differentiation and collagen deposition.

Related Concept Videos